Navigation Links
Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting

ough 36 weeks post-menstrual age (PMA), and

* fewer days on mechanical ventilation.

Dr. Bose commented, "The data from this Phase 2 estimation trial are encouraging. These data support the continued evaluation of Surfaxin as a therapeutic option for the prevention of BPD."

Discovery's Phase 2 clinical trial enrolled 136 premature infants. In addition to standard of care, patients were randomized to receive either Surfaxin standard dose (175 mg/kg), Surfaxin low dose (90 mg/kg), or sham air as a control. The trial was designed as an estimation study to evaluate the safety and potential efficacy of Surfaxin in infants at risk for BPD, and was not powered to determine statistically significant differences in outcomes. The Surfaxin standard dose (175 mg/kg) is the dose that was administered in Discovery's RDS Phase 3 clinical trials. No meaningful conclusions could be drawn from the Surfaxin low dose (90 mg/kg) treatment group, as infants randomized to this arm had more pre-existing medical risk factors compared with the Surfaxin standard dose (175 mg/kg) group and the control group.

Aerosurf(tm) (aerosolized KL-4 surfactant) delivered via the Chrysalis Technologies novel capillary aerosol generator device

Data from previously conducted pre-clinical studies using aerosolized KL-4 surfactant were also presented to the medical community for the first time. In these studies, KL-4 surfactant was aerosolized to compare Chrysalis' novel, investigational capillary aerosol generator technology to commercially available aerosol generator devices. The studies demonstrated that Aerosurf maintains its chemical structure and essential functional activity post-aerosolization. In addition, the Chrysalis investigational capillary aerosol generator technology generated a nearly 10-fold higher aerosol output rate than the other study devices.

Discovery Labs, in collaboration with Chrysalis, is developing an integrated drug device system that comb
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
3. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:11/30/2008)...ec. 1 Abnormalities in ...in children with autism spectrum disorder by using...y presented today at the annual meeting of the Rad..., "Using MEG, we can record the tiny magnetic fi...aid Timothy Roberts, Ph.D., vice chair of research...
(Date:11/26/2008)...information density, automation and intelligent cl...trasound to an all new level , , CHICAGO, I...Healthcare ( www.siemens.com/healthcare ) highli...Scanner (ABVS)(1), the world,s first multi-use, a...4th Scientific Assembly and Annual Meeting of the ...
(Date:11/25/2008)...FRANCISCO, Calif., Nov. 25 Proteol...nt of novel therapeutics that target,protein degr..., today,announced that data from two ongoing Phas...eloma will be presented at the upcoming 50th Annua...ASH). Carfilzomib is the first in a new class,of...
(Date:11/24/2008)... Ill., and OSAKA, Japan, Nov. 24 T...y-owned subsidiary, Takeda Global Research & D...t the Arthritis Advisory Committee of the U.S. Foo...he FDA approve febuxostat for the treatment of hy... to zero in favor of approval, with one panel memb...
Breaking Medicine Technology:Brain Waves Show Sound Processing Abnormalities in Autistic Children 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 3Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3Bad News to Bad Bugs 3A Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity 2567 1Bad News to Bad Bugs 3A Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity 2567 2SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen 28R 29 Versus Supportive Care in Patients With Myelodysplastic Synd 2565 1SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen 28R 29 Versus Supportive Care in Patients With Myelodysplastic Synd 2565 2SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen 28R 29 Versus Supportive Care in Patients With Myelodysplastic Synd 2565 3SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen 28R 29 Versus Supportive Care in Patients With Myelodysplastic Synd 2565 4Pressure Cycling Technology 28PCT 29 Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer Str 2563 1Pressure Cycling Technology 28PCT 29 Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer Str 2563 2Pressure Cycling Technology 28PCT 29 Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer Str 2563 3 Great Doctors Produce Great Results 28Healthcare Underwriters Group Mutual of Ohio Pays A Cash Dividend 29 3A Healthcare Underwriters Group Mut 23009 1 Great Doctors Produce Great Results 28Healthcare Underwriters Group Mutual of Ohio Pays A Cash Dividend 29 3A Healthcare Underwriters Group Mut 23009 2
...NGELES & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ap...maceutical company focused on,the discovery and de...ay announced encouraging preclinical data of AV-41...nhibitor of EGFR/HER2 using,AVEO,s unique EGFR mut...he results from the preclinical study showed that ...
...r Presentation on April 17, 2007 at AACR, SAN DIEG...aceuticals, Inc. presented data from an in vitro s...promotes natural killer (NK),cell-mediated anti-tu...ysis of tumor cells and enhanced antibody-dependen...esentation at the Annual,Meeting of the American A...
Other Medicine Technology:AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 2AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 3AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 4Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells 2Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells 3Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells 4
(Date:12/2/2008).... 2 With the bright lights, sweet ...olidays may be an exciting time of year for any ch... especially with today,s tough economy. Whether i...tying their wallets, or spending hours traveling t...lax, and even less time to be alone and romantic w...
(Date:12/2/2008)...ologic-Treated Psoriasis Patients Will Double by 2...rces , , WALTHAM, Mass., Dec. 2 /PRNewswire...g research and advisory firms for pharmaceutical a...particularly Centocor/Janssen-Cilag,s Stelara and ...severe psoriasis drug market to more than double t...
(Date:12/2/2008)... New research estimates that 1500 l... with the highest risk-adjusted,mortality rates (...ery,performed as well as hospitals with the lowes...ity rate for women was higher than men regardless ...eased as performance declined.,The study ranked U...
(Date:12/2/2008)... 2 Mylan Inc. (NYSE: M...Mylan Pharmaceuticals Inc., have entered,into a s...Corp., Novartis,Corp. and Novartis International ...ion of Novartis, Femara(R). , Mylan,s Vice ...e very,pleased to have reached this agreement, wh...
Breaking Medicine News(10 mins):Health News:Jennie Finch Shares how to Fire up the Romance Despite the Demands of the Holidays 2Health News:Jennie Finch Shares how to Fire up the Romance Despite the Demands of the Holidays 3Health News:Biologic Drugs, Particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017 2Health News:New Research Estimates 1500 Lives Could Be Saved Annually if the Lowest Performing Hospitals for Coronary Artery Bypass Graft Surgery Performed as Well as Top-ranking Hospitals 2Health News:New Research Estimates 1500 Lives Could Be Saved Annually if the Lowest Performing Hospitals for Coronary Artery Bypass Graft Surgery Performed as Well as Top-ranking Hospitals 3Health News:Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity 2
...be a promising treatment, according to a new study...ecial needle into the tumor. A current is then pas...sue and ablate, or eliminate, it. The research fin... also do not appear to have any serious complicati...
...n treatment for a specific type of testicular canc...pically treated by // removal of the testicle foll... of developing a second cancer in another organ up...ed more than 540 patients to receive a single cour...
...a new vaccine to children. Researchers found that ...nvasive pneumococcal disease (pneumonia or meningi... 2002, 14,730 fewer cases occurred among whites an...d with the average number in two prevaccine years,...
...ion that can cause death within days or even hours...ive care intended to keep patients alive long enou...r a donor organ becomes available for transplantat... die unless they receive a liver transplant. A bio...
Other Medicine News:
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
Medicine Products: